Long-acting synthetic oxytocin analog used for prevention of postpartum hemorrhage; approved in many countries, not FDA approved.
Oxytocin analog with a deamino modification and carbon substitution. Longer half-life than oxytocin; heat-stable formulation (Pabal) for low-resource settings.
Evidence summary in progress. See the citations section below for the underlying research papers.
No FDA label or editorial side-effect profile is on file for this compound yet. See the clinical trials and citations sections for study-reported safety data.
No documented drug interactions on file.
Not FDA approved. Approved in Canada, Europe, and many other countries for prevention of postpartum hemorrhage.
Not available via 503A/503B compounding pharmacies.
Regulatory data last verified 4/19/2026
Showing 12 of 25 indexed studies. View all on ClinicalTrials.gov →
Showing 20 of 29 papers. View all on PubMed →